Epigenomics taps up Taapken
This article was originally published in Scrip
Executive Summary
Epigenomics AG, the German-American cancer molecular diagnostics company, has appointed Dr. Thomas Taapken to serve as acting Chief Executive Officer in addition to his responsibilities as Chief Financial Officer, effective 1 October 2012. Dr Taapken replaces Geert Nygaard who agreed with Epigenomics' supervisory board that he will leave the company effective 30 September, 2012.